A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data from controlled studies concerning the response rates of patients to a second antidepressant medication after they have been unresponsive to a systematic trial of another antidepressant are extremely useful to clinicians for rational prescription of pharmacotherapy. Such information allows making an accurate prognosis, sustaining realistic hope in the patient, and achieving the best possible therapeutic outcome. This study was designed to add to the scanty literature available on this subject. METHOD: Eighty-nine mood-reactive, nonmelancholic, mainly chronically depressed outpatients at a university research clinic who were unresponsive to vigorous double-blind trials of imipramine or phenelzine were crossed over to treatment with the other drug under double-blind conditions. RESULTS: Of 46 patients previously unresponsive to imipramine who completed phenelzine treatment, 31 (67%) responded to phenelzine. Of 22 patients previously unresponsive to phenelzine who completed imipramine treatment, nine (41%) responded to imipramine. The difference in response rates was statistically significant. Even after they had shown no response to 7 weeks of placebo and 6 weeks of imipramine treatment, 10 (83%) of 12 patients who then completed treatment with phenelzine responded. CONCLUSIONS: These data suggest that among chronically ill, mood-reactive depressed patients with many symptoms of atypical depression, phenelzine is strikingly effective in those who have been nonresponders to imipramine and should be tried in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.2.195 · Cited by 167
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
(2007) · PubMed · Cited by 453
Anderson, I. M., Nutt, D. J., & Deakin, J. F. W. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400101 · Cited by 310
MAOIs in the Contemporary Treatment of Depression
Thase, M. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00058-8 · Cited by 301
Papakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?
Joffe, H., & Cohen, L. S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00169-3 · Cited by 283
Pharmacology of Antidepressants
Frazer, A. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199704001-00002 · Cited by 269
Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
Dopaminergic-based pharmacotherapies for depression
Papakostas, G. I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.12.002 · Cited by 168
“, 2002); their use mainly limited for treatment-resistant depression (TRD) (McGrath et al., 1993; Thase et al., 1992; McGrath et al., 1987a).”
BackgroundTreatment of depression with atypical features: a meta-analytic approach
Henkel, V., Mergl, R., Allgaier, A.-K., Kohnen, R., Möller, H.-J., & Hegerl, U. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.07.012 · Cited by 161
A History of the Concept of Atypical Depression
Davidson, J. R. T., & Thase, M. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0207e03 · Cited by 119
“In a crossover design study, McGrath et al.29 compared the efficacy of phenelzine and imipramine in nonresponders.”
MethodPotential Roles of microRNAs in the Regulation of Monoamine Oxidase A in the Brain
Higuchi, Y., Soga, T., & Parhar, I. S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00339 · Cited by 22
“Several lines of evidence suggested that MAO inhibitors are effective for tricyclic antidepressant-resistant depression (Thase et al., 1992; McGrath et al., 1993).”
Background
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1993-01-01
- Volume
- 150
- Issue
- 1
- Pages
- 118-123
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2414226714
- Cited by
- 101
- References
- 2
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.